Thu, Nov 02, 2017 - Page 11 News List

Mylan woes worsen amid probe into top executive


Mylan NV’s latest troubles could not come at a worse time.

Two years ago, Mylan was a swaggering drugmaker on the way up, buying up rivals as it grew and diversified.

Then it faced political scrutiny over price hikes for its EpiPen allergy shot and increasing pressure on prices for the generic drugs that are the company’s backbone.

In August, Mylan cut its outlook for next year, and on Tuesday came another blow: Its No. 2 executive was one of the first two top managers accused in an industry-wide civil investigation of colluding in a “sinister” conspiracy to prop up prices.

After reaching an all-time high of US$76.06 in April 2015, its shares have been cut in half and closed on Tuesday at US$35.71, dropping 6.6 percent for the day.

Like other drugmakers, Mylan has been under increasing pressure from regulators at the US Food and Drug Administration (FDA) over the past year.

Taking up US President Donald Trump’s call to reduce drug prices, the FDA has said it will accelerate the approval of copycat drugs that will push prices down further. The agency has said it will specifically target drugs that only have a few generic competitors, trimming the industry’s already thin margins further.

The multi-year civil case against Mylan and 17 other makers of generic pills — with a dragnet that could wrap in other senior drug executives around the industry — could prove damaging.

Not only does it target Mylan president Rajiv Malik, but the alleged conduct in the complaint supposedly helped generic-drug makers preserve their margins and markets, avoiding some of the competition that has already been pressuring the industry.

In their 243-page complaint, 45 US states and Washington said that more than a dozen drugmakers worked together to share the market and avoid a “fight to the bottom.”

At industry conferences, over dinner parties and hundreds of telephone calls, e-mails and text messages, executives would agree to raise or maintain prices for specific drugs in tandem or delineate each company’s market share.

Malik is one of two senior drug executives named in the new complaint, in which the states are seeking to expand an earlier lawsuit alleging price and market fixing.

Mylan, which is also named as a defendant in the case, said it stands behind Malik and will “defend this case vigorously.”

Malik’s lawyer, Robert Cleary of Proskauer Rose LLP, said in a telephone interview that the executive “emphatically and categorically denies the allegations in the complaint” and “is confident he will be completely vindicated.”

The complaint details numerous telephone calls and e-mails between Malik and executives at closely held Indian drugmaker Emcure Pharmaceuticals Ltd and its subsidiary, Heritage Pharmaceuticals, around the time when Heritage launched an antibiotic called Doxy DR.

Mylan — then the only other generic maker with that pill on the market — agreed to give up two large accounts to Heritage, helping Heritage enter the market without putting pressure on prices, the filling said.

“Given direct involvement of executives in this case and the evidence we had implicating them, we felt as a group of antitrust enforcers that it was important to hold these individuals accountable,” Connecticut Assistant Attorney General Joseph Nielsen said on Tuesday on a conference call with reporters.

This story has been viewed 2114 times.

Comments will be moderated. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned.

TOP top